Managing Chronic Liver Disease in Older Adults with Multiple Comorbidities

Initial Assessment and Risk Stratification

The American Geriatrics Society recommends recognizing that older adults with chronic liver disease and multiple comorbidities require a multidisciplinary team approach with careful medication selection, and establishing goals of care aligned with patient preferences, quality of life, and realistic prognosis rather than disease-specific targets 1, 2

The European Society of Cardiology suggests using cardioselective beta-blockers, such as carvedilol, which reduces portal hypertension in cirrhosis, controls hypertension, manages atrial fibrillation rate, and has demonstrated mortality benefit in heart disease 3, 5
The American Heart Association recommends targeting systolic BP <140 mmHg if patient is <80 years old, or 140-145 mmHg if ≥80 years old, and avoiding diastolic BP <70 mmHg to prevent coronary hypoperfusion 4, 3, 6

The European Heart Journal suggests conducting structured periodic medication reviews matching each medication to current comorbidities and goals of care, and prioritizing medications that treat multiple conditions simultaneously, such as carvedilol for portal hypertension, hypertension, and atrial fibrillation rate control 1, 7

The American Heart Association recommends regular blood pressure monitoring for orthostatic hypotension, especially after medication changes, and monitoring renal function and electrolytes, particularly with diuretics and RAAS inhibitors in liver disease 4, 6, 7

The European Heart Journal and the Journal of the American Geriatrics Society recommend coordinating care between cardiology, hepatology, and primary care to avoid contradictory recommendations, and involving a pharmacist for medication reconciliation and interaction screening 1, 2